e-therapeutics plc
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 to trea… Read more
e-therapeutics plc - Asset Resilience Ratio
e-therapeutics plc (ETXPF) has an Asset Resilience Ratio of 50.57% as of January 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2022)
This chart shows how e-therapeutics plc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down e-therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $20.24 Million | 50.57% |
| Total Liquid Assets | $20.24 Million | 50.57% |
Asset Resilience Insights
- Very High Liquidity: e-therapeutics plc maintains exceptional liquid asset reserves at 50.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
e-therapeutics plc Industry Peers by Asset Resilience Ratio
Compare e-therapeutics plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for e-therapeutics plc (2012–2022)
The table below shows the annual Asset Resilience Ratio data for e-therapeutics plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-01-31 | 50.99% | $20.24 Million | $39.69 Million | +20.35pp |
| 2021-01-31 | 30.64% | $6.02 Million | $19.65 Million | +14.67pp |
| 2020-01-31 | 15.98% | $1.01 Million | $6.31 Million | -5.28pp |
| 2018-01-31 | 21.25% | $3.56 Million | $16.73 Million | -31.73pp |
| 2017-01-31 | 52.98% | $11.95 Million | $22.56 Million | -9.55pp |
| 2016-01-31 | 62.53% | $26.24 Million | $41.97 Million | -21.34pp |
| 2015-01-31 | 83.86% | $32.00 Million | $38.16 Million | +4.41pp |
| 2014-01-31 | 79.46% | $36.25 Million | $45.62 Million | +31.06pp |
| 2013-01-31 | 48.40% | $5.55 Million | $11.47 Million | -2.36pp |
| 2012-01-31 | 50.76% | $7.75 Million | $15.27 Million | -- |